February 20, 2025 • Denver, CO: AOA Dx is excited to announce its membership in the BLOODPAC (Blood Profiling Atlas in Cancer) Consortium, a public-private initiative aimed at accelerating the development, validation, and accessibility of liquid biopsy tests. AOA Dx is advancing the fight against ovarian cancer by developing the AKRIVIS GD test, an innovative early detection multi-omic test utilizing gangliosides, lipids, and proteins in symptomatic women.
By joining BLOODPAC, AOA Dx aims to contribute its lipidomic research and multi-omics expertise to the broader liquid biopsy community. AOA’s research is focused on harnessing the power of multi-omics and machine learning to develop an urgently required early detection test for women who present with signs and symptoms of ovarian cancer. AOA Dx’s state-of-the-art laboratory in Denver is pioneering the use of lipidomics for early cancer detection, with a goal of improving outcomes for patients through earlier, more accurate diagnostics.
“We are thrilled to be part of BLOODPAC and contribute to the ongoing efforts to develop standards and frameworks for cancer detection,” said Oriana Papin-Zoghbi, CEO of AOA Dx. “Our research, particularly in lipidomics, will support the development of standards and best practices for liquid biopsy assays. This partnership provides an incredible opportunity for us to learn from others and share our insights on multi-modal data integration and machine learning for better cancer detection.”
As a member of BLOODPAC, AOA Dx intends to participate in the consortium’s new Multi-Omics and Early Detection and Screening Working Groups. In 2025, AOA Dx plans to publish a series of abstracts and papers showcasing the potential of combining gangliosides, lipids, and proteins for early cancer detection. These findings will be shared in the BLOODPAC Portal upon their release, furthering the efforts to integrate liquid biopsy into routine clinical practice.
“Achieving better outcomes for cancer patients requires collaboration, and we are delighted to welcome AOA DX as a BLOODPAC member to help advance this mission,” said Lauren Leiman, Executive Director at BLOODPAC. “The company’s work to develop the first early detection test for ovarian cancer means they are well-positioned to contribute important expertise and insights to our recently-expanded efforts, focused on developing standards and frameworks for multi-omic assays for early detection.”
About BLOODPAC
BLOODPAC is a public-private consortium aimed at accelerating the development, validation, and accessibility of liquid biopsy assays to better inform medical decisions and ultimately improve patient care and outcomes.
About AOA Dx:
AOA Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in lipidomics and proprietary biomarker technology. Our revolutionary multi-omic platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx is developing AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer. We foresee novel tumor biomarker gangliosides, combined with other lipids, proteins and machine learning, as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers.